Article
Risk of Treatment-Related Toxicities from EGFR Tyrosine Kinase Inhibitors: A Meta-analysis of Clinical Trials of Gefitinib, Erlotinib, and Afatinib in Advanced EGFR-Mutated Non-Small Cell Lung Cancer.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer - 1 Apr 2017
Ding Pei Ni, Lord Sarah J, Gebski Val, Links Matthew, Bray Victoria, Gralla Richard J, Yang James Chih-Hsin, Lee Chee Khoon
Abstract excerpt
INTRODUCTION: Gefitinib, erlotinib, and afatinib are tyrosine kinase inhibitors (TKIs) used for treatment of advanced EGFR-mutated NSCLC. Estimating differences in toxicity between these EGFR TKIs is important for personalizing treatment. METHODS: We performed a meta-analysis of randomized trials that compared EGFR TKI therapy against chemotherapy or placebo. We extracted data from the EGFR TKI arm for indirect...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.